MuscleSubcutaneous

Ipamorelin

10mg Vial

Typical Dose

100–300 mcg

Frequency

Nightly or 2x/day

Half-Life

~2 hours

Research-use dosing; specific study population not established.

Ipamorelin Overview

Mechanism of Action

Ipamorelin is a pentapeptide selective growth hormone secretagogue that mimics ghrelin at the GHS-R1a receptor on pituitary somatotrophs. Unlike other GH secretagogues (GHRP-6, hexarelin), Ipamorelin does not significantly affect cortisol, prolactin, or appetite — making it one of the cleanest GH-stimulating peptides available. It triggers GH release in a dose-dependent, pulse-like fashion.

Half-Life

~2 hours

Timing

Before bed (amplifies natural GH pulse). If split dosing, also upon waking.

Injection Site

Subcutaneous, lower abdomen

Food

Fast 2+ hours before. GH release blunted by glucose/insulin.

Common Stacks

  • CJC-1295 no DAC — The gold standard GHRH+GHRP stack
  • Tesamorelin — Alternative GHRH pairing

Ipamorelin Dosing Protocol

Standard Protocol

8–12 weeks

100–300 mcg nightly

Best combined with CJC-1295 (no DAC) for synergistic effect.

Split Dosing

8–12 weeks

100–200 mcg 2–3x/day

Multiple smaller pulses throughout the day. Often morning + night.

Ipamorelin Expected Timeline

Week 1–2

Improved sleep onset and depth

Week 3–4

Enhanced recovery; reduced post-exercise soreness

Week 6–8

Visible fat loss; improved skin elasticity

Week 8–12

Body composition improvement; sustained energy

Ipamorelin Side Effects

Mild hunger increase (less than GHRP-6)

Head rush post-injection (transient)

Water retention (mild)

Ipamorelin Research Studies

Ipamorelin, the first selective growth hormone secretagogue

Raun K, Hansen BS, Johansen NL, et al. — Eur J Endocrinol (1998)

Landmark study establishing ipamorelin as the first truly selective GH secretagogue, demonstrating potent GH release without affecting ACTH, cortisol, prolactin, or FSH/LH levels.

PubMed: 9916862

Growth hormone secretagogues: history, mechanism of action, and clinical development

Ghigo E, Arvat E, Camanni F — Ann Endocrinol (2002)

Review of GHS mechanisms confirming ipamorelin’s selectivity profile and clinical applicability for age-related GH decline.

PubMed: 12191096

Ipamorelin FAQ

How is Ipamorelin different from GHRP-6?

Both stimulate GH release via the ghrelin receptor, but GHRP-6 also significantly increases cortisol, prolactin, and appetite. Ipamorelin is selective — it releases GH without those unwanted side effects, making it the preferred choice.

Can I take Ipamorelin during the day?

Yes. Split dosing (morning + bedtime) creates multiple GH pulses. Just ensure you’re fasted for at least 2 hours before each dose, as insulin and blood sugar suppress GH release.

Related Protocols